Business Information
The group's principal activity is to develop oncology drugs, like TOCOSOL Paclitaxel & TOCOSOL Camptothecin, that provide therapeutic alternatives for cancer patients. It has developed the TOCOSOL (TM) drug delivery technology platform to formulate injectable drugs that target cancer, diabetes, bacterial infections and cardiovascular disease. In October 2005, the Company entered into a collaboration and license agreement with Schering AG, a German corporation, and granted an exclusive, worldwide license to its TOCOSOL Paclitaxel anti-cancer product. The company's facility is located in Bothell, Washington.
|
|
Name |
Title
|
Email
|
| Robert Ivy | Chmn. | N/A | | Alan Fuhrman | Dir., Sr. VP, CFO | N/A | | Richard Daifuku | Acting Chief Medical Officer, VP - Preclinical, Clinical Research | N/A | | Craig Eudy | VP, Controller | N/A | | Dean Kessler | VP - Preclinical Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 22,392 | (23,551) | | 2005 | 8,254 | (21,097) | | 2004 | N/A | (16,311)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
